IgA Nephropathy (IgAN ... focuses on disease management and slowing disease progression. Also known as Berger’s disease, IgAN is an autoimmune disease that occurs when an antibody known as ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

For more information, visit travere.com. About IgA Nephropathy (IgAN) IgAN, also called Berger’s disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

This provided the funding needed to take its formulation of budesonide into late stage trials for the rare disease, IgA nephropathy, also known as Berger’s disease or IgAN. Its technology is ...

After four years of heartbreak and a promise to his sister, Junction’s Aidan Cardwell looked to the sky—then finally stood atop the podium in Austin.

Thousands of people living with chronic kidney disease in England could soon benefit from a new treatment, following final ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...